
    
      SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a
      new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase
      inhibitor (TKI). A disease-control rate of 61.1% and a mPFS of 4.7 months were showed in
      Apatinib phase II study in patients with NSCLC.
    
  